The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2023
year mood +0.28 · +0.20 to +0.40 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan +0.20 Feb Mar Apr May Jun Jul Aug +0.40 Sep Oct Nov Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.20+0.20+0.20+0.20+0.30+0.30+0.30+0.40+0.23+0.30+0.34+0.40

Novo Nordisk tops LVMH; Wegovy cardiovascular-benefit data

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 06, 2026
Top healthcare stories of 2023
Sep
Novo Nordisk briefly overtakes LVMH as Europe's most valuable company cnbc.com →

Novo Nordisk surged past LVMH in market value, driven by strong demand for its weight-loss drugs Ozempic and Wegovy, amid positive clinical results and robust sales growth. The Danish drugmaker's market cap reached $421 billion, briefly surpassing LVMH's $421 billion, reflecting investor confidence in its healthcare innovations. This shift underscores a broader market trend favoring pharmaceutical and metabolic health advancements over luxury goods, especially as LVMH faces headwinds from weakening Chinese consumer spending.

Nov
FDA approves Eli Lilly's Zepbound for weight loss, boosting obesity drug market cnbc.com →

The FDA approved Eli Lilly's tirzepatide, marketed as Zepbound, for chronic weight management in adults with obesity or overweight with related conditions, expanding its use beyond Type 2 diabetes treatment Mounjaro. The approval positions Eli Lilly as a major competitor to Novo Nordisk in the rapidly growing $100 billion potential obesity drug market, with Zepbound expected to launch by year-end at $1,060 per month. While the drug demonstrated up to 22.5% average weight loss in trials, market implications include ongoing challenges with insurance coverage, potential supply constraints, and safety monitoring for side effects like pancreatitis and suicidal ideation.